LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty In Study

Longeveron said that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo.

Shares of Longeveron Inc. (LGVN) rose 7% on Wednesday after the company announced positive results from the trial of its investigational therapy in age-related clinical frailty.

The company said that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo.

Laromestrocel is a human bone marrow-derived allogeneic stem cell (MSC) investigational therapy. The company was evaluating whether it improves physical functioning in 148 ambulatory individuals with frailty. 

Get updates to this developing story directly on Stocktwits.<